ArticleBlood advances2026
Increased gene therapy efficacy through the use of extended half-life clotting factors.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Doing more with less in hemophilia B gene therapy.Blood advances · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThe development of more effective gene therapy strategies for hemophilia B remains essential because results of multiple clinical trials show significant interpatient variability in clinical outcomes, with a fraction of patients (up to 13%) even returning to prophylaxis. Another major challenge in current adeno-associated viral (AAV)-based gene therapy for hemophilia B pertains to dose-dependent vector-related immune responses, requiring immune suppression. We investigated whether combining gene therapy with transgenes encoding extended half-life (EHL) coagulation factors could enhance therapeutic efficacy. AAV vectors encoding a hyperactive factor IX variant R338L (ie, FIX-Padua), genetically fused to a mutant human albumin (FIX-R338L-ALB[QMP]), were administered to both wild-type and hemophilia B mice. These chimeric transgenes were codon-optimized and driven by a hepatocyte-specific promoter. The AAV-FIX-R338L-ALB(QMP) vector demonstrated significantly improved efficacy compared with the control AAV-FIX-R338L vector, resulting in a sustained fourfold and threefold increase in FIX antigen levels and activity, respectively. These increases were consistent with durable correction of the bleeding phenotype. Importantly, immunogenicity or liver toxicity was not increased because no anti-FIX antibodies, alanine transaminase elevations, or liver immune infiltrations were detected after treatment. Furthermore, immune tolerance was achieved in most hemophilia B mice treated with AAV-FIX-R338L-ALB(QMP), even after active immunization with FIX protein and adjuvant, which was found to be mediated by regulatory T cells. In addition, no increase in thrombogenic risk was observed, indicated by stable D-dimer levels. These findings support the potential of FIX-R338L-ALB(QMP) fusion constructs encoding EHL FIX as a promising next-generation gene therapy for hemophilia B.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.